The Medical Advisor

Why Metabolism Is the Missing Link in Modern Medicine Cancer prevention, longevity, and metabolic health are usually discussed as separate domains. Oncology focuses on mutations. Aging research focuses on senescence and epigenetics. Metabolic health is reduced to weight, glucose, or cholesterol. This siloed thinking misses a deeper unifying driver. The common thread connecting cancer risk, cancer outcomes, and biological aging is metabolic signaling —specifically insulin resistance and mitochondrial dysfunction. This article lays out a single, coherent framework: Insulin resistance drives mitochondrial dysfunction, which erodes metabolic flexibility. That environment accelerates aging and creates fertile ground for cancer. 1. Insulin Resistance Is Not a Blood Sugar Problem Insulin resistance (IR) is often framed as a pre-diabetic condition. In reality, it is a whole-cell signaling disorder . When insulin signaling is impaired: Cells fail to take up glucose efficiently Circulating insul...

Abstract Background: Drug repurposing has emerged as a strategy in oncology to identify low-cost, widely available agents with potential anticancer activity. Antiparasitic benzimidazoles (fenbendazole, mebendazole) and the macrocyclic lactone ivermectin have been proposed as adjunctive therapies in breast cancer based on preclinical mechanistic data and anecdotal clinical reports. Interest has grown within integrative oncology communities, particularly for advanced or treatment-resistant disease. Objective: To compile and summarize reported case experiences describing the use of fenbendazole, ivermectin, and mebendazole in patients with breast cancer, and to outline proposed biological mechanisms and current evidence gaps. Methods: Publicly available case reports, patient testimonials, and practitioner-shared clinical narratives involving breast cancer patients who used fenbendazole, ivermectin, or mebendazole were reviewed and categorized by disease stage, concurrent conventiona...